A Study of NB003 in Patients With Advanced Malignancies

Phase 1 Completed 258 enrolled Ningbo Newbay Technology Development Co., Ltd

NaSingle-groupOpen-labelTreatment

Summary

This a A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of NB003 in Subjects with Advanced Malignancies

Timeline

Start: 2021-08-06
Primary completion: 2025-08-01
Completion: 2025-08-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NB003	Unknown	—	Oral

A Study of NB003 in Patients With Advanced Malignancies

Summary

Timeline

Drugs

Indications